- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Smith, I.E., Pierga, J.Y., Biganzoli, L., Cortés-Funes, H., Thomssen, C., Pivot, X., Fabi, A., Xu, B., Stroyakovskiy, D., Franke, F.A., Kaufman, B., Mainwaring, P., Pienkowski, T., De Valk, B., Kwong, A., González-Trujillo, J.L., Koza, I., Petrakova, K., Pereira, D., Pritchard, K.I. Ann. Oncol. (2011)